在性结肠炎患者中重新使用HMGCO-A降解酶抑制剂阿托瓦斯:一项随机对照研究
Hayam Ali AlRasheed1, Sahar M El-Haggar2, Sahar K Hegazy2,3
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Addulrahman University, Riyadh 84428, Saudi Arabia.
阿托瓦斯塔丁可能有助于性结肠炎 (UC) 患者. 这项研究发现,阿托瓦斯塔丁与安慰剂相比,在UC患者中显著降低了疾病活性和关键生物标志物如松林和骨髓氧化酶.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
背景情况:
- 性结肠炎 (UC) 是一种普遍存在的炎症性肠病,影响全球数百万人.
- 尽管进行了临床前研究,但阿托瓦斯塔丁在UC中的疗效临床证据有限.
- 脑膜炎的症状包括腹,直肠出血,腹痛和体重减轻.
研究的目的:
- 评估阿托瓦斯塔丁在性结肠炎患者的保护作用.
- 评估阿托瓦斯塔丁对便骨髓氧化酶,血清血红素和疾病活性指数 (DAI) 的影响.
主要方法:
- 一项为期六个月的随机试验,涉及轻度至中度UC患者.
- 对照组接受了梅萨拉和安慰剂;阿托瓦斯塔丁组接受了梅萨拉和阿托瓦斯塔丁 (每天80毫克).
- 通过DAI评估疾病的严重程度;治疗前和后测量血清佐努林和便骨髓氧化剂.
主要成果:
- 两组都显示了DAI,佐努林和髓氧化酶的显著减少.
- 阿托瓦斯塔丁组在DAI (p=0.001),佐努林 (p=0.04) 和髓氧化酶 (p=0.03) 中显著减少.
- 在阿托瓦斯塔丁组中发现了DAI和佐努林 (r=0.4) 和髓氧化酶 (r=0.36) 之间的显著相关性.
结论:
- 同时服用阿托瓦斯塔丁显示出作为性结肠炎的辅助治疗的潜力.
- 这些发现表明,阿托瓦斯塔丁可能会调节UC的关键炎症标志物.
- 需要进一步的研究来证实阿托瓦斯塔丁在UC管理中的作用.
更多相关视频
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Treatment of Constipation-Predominant IBS
